{"id":16640,"date":"2025-02-04T15:16:16","date_gmt":"2025-02-04T15:16:16","guid":{"rendered":"https:\/\/www.tun.com\/home\/?p=16640"},"modified":"2025-02-04T15:16:17","modified_gmt":"2025-02-04T15:16:17","slug":"common-binge-eating-treatment-shows-mixed-results-study-finds","status":"publish","type":"post","link":"https:\/\/www.tun.com\/home\/common-binge-eating-treatment-shows-mixed-results-study-finds\/","title":{"rendered":"Common Binge Eating Treatment Shows Mixed Results, Study Finds"},"content":{"rendered":"\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-uagb-blockquote uagb-block-e7eb3fc3 uagb-blockquote__skin-border uagb-blockquote__stack-img-none\"><blockquote class=\"uagb-blockquote\"><div class=\"uagb-blockquote__content\">A Rutgers Health-led study highlights mixed results for lisdexamfetamine as a treatment for binge eating disorder, shedding light on the need for more targeted medications.<\/div><footer><div class=\"uagb-blockquote__author-wrap uagb-blockquote__author-at-left\"><\/div><\/footer><\/blockquote><\/div>\n\n\n\n<div class=\"wp-block-group is-content-justification-space-between is-nowrap is-layout-flex wp-container-core-group-is-layout-0dfbf163 wp-block-group-is-layout-flex\"><div style=\"font-size:16px;\" class=\"has-text-align-left wp-block-post-author\"><div class=\"wp-block-post-author__content\"><p class=\"wp-block-post-author__name\">The University Network<\/p><\/div><\/div>\n\n\n<div class=\"wp-block-uagb-social-share uagb-social-share__outer-wrap uagb-social-share__layout-horizontal uagb-block-ee584a31\">\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-ec619ce7\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/www.facebook.com\/sharer.php?u=\" tabindex=\"0\" role=\"button\" aria-label=\"facebook\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M504 256C504 119 393 8 256 8S8 119 8 256c0 123.8 90.69 226.4 209.3 245V327.7h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.28c-30.8 0-40.41 19.12-40.41 38.73V256h68.78l-11 71.69h-57.78V501C413.3 482.4 504 379.8 504 256z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-32d99934\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/twitter.com\/share?url=\" tabindex=\"0\" role=\"button\" aria-label=\"twitter\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-1d136f14\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/www.linkedin.com\/shareArticle?url=\" tabindex=\"0\" role=\"button\" aria-label=\"linkedin\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\"><path d=\"M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<p>Researchers led by Rutgers Health unveiled a study that reveals mixed outcomes for patients using lisdexamfetamine, marketed as Vyvanse, a commonly prescribed stimulant for binge eating disorder (BED).<\/p>\n\n\n\n<p>&#8220;Binge eating disorder is the most common eating disorder in the United States, yet there is no drug specifically developed for the condition that affects people of all racial and ethnic groups,&#8221; lead author Abanoub Armanious, a master of science student at Rutgers School of Public Health, said in a <a href=\"https:\/\/sph.rutgers.edu\/news\/common-treatment-binge-eating-disorder-shows-mixed-results\" target=\"_blank\" rel=\"noopener\" title=\"\">news release<\/a>.<\/p>\n\n\n\n<p>Originally approved by the Food and Drug Administration (FDA) for the treatment of ADHD, lisdexamfetamine later received approval for moderate to severe BED in adult patients due to its effectiveness in reducing the frequency of binge eating episodes. <\/p>\n\n\n\n<p>&#8220;[I]ts ability to also reduce the frequency of binge eating episodes led to its approval for binge eating disorder,&#8221; added senior author Morgan James, an assistant professor of psychiatry and member of the Rutgers Addiction Research Center at the Brain Health Institute.<\/p>\n\n\n\n<p>The study, <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2772598724000412\" target=\"_blank\" rel=\"noopener\" title=\"\">published<\/a> in the journal Psychiatry Research Communications, digs into patients&#8217; subjective experiences with lisdexamfetamine. Although many reported a decrease in binge episodes and better appetite control, others encountered significant side effects and inconsistent efficacy.<\/p>\n\n\n\n<p>BED is characterized by recurrent episodes of eating large quantities of food, often quickly and to the point of discomfort, accompanied by a sense of loss of control. This disorder is frequently associated with depression, anxiety and obesity-related health issues like Type 2 diabetes.<\/p>\n\n\n\n<p>Although clinical trials have proven lisdexamfetamine&#8217;s effectiveness in reducing binge episodes for some, patient-centered qualitative data had been scarce until now. <\/p>\n\n\n\n<p>&#8220;The repositioning of this drug from an ADHD medication to a treatment for binge eating disorder highlights a critical gap in the treatment landscape. as no drug has been specifically developed and FDA-approved for binge eating disorder, despite the disorder&#8217;s widespread prevalence both in the U.S. and globally,\u201d Armanious added. <\/p>\n\n\n\n<p>For this study, the researchers conducted a thematic analysis of 111 anonymous reviews from self-identified BED patients on Drugs.com. They analyzed the relationship between patients&#8217; subjective experiences with lisdexamfetamine and their ratings of the drug&#8217;s efficacy. <\/p>\n\n\n\n<p>\u201cOur findings revealed that higher perceived efficacy was associated with improved focus and fewer side effects, while lower ratings were linked to concerns about diminishing therapeutic effects, insomnia and afternoon energy loss,\u201d added Armanious.<\/p>\n\n\n\n<p>Key challenges identified with lisdexamfetamine include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Many patients face the highest risk of binge eating at night, but the drug&#8217;s effects generally diminish by evening, leaving them vulnerable.<\/li>\n\n\n\n<li>The &#8220;crash&#8221; from the medication often results in fatigue, irritability or mental fog.<\/li>\n\n\n\n<li>Some patients attempted to adjust dosage timings, which frequently led to insomnia and other sleep issues.<\/li>\n<\/ul>\n\n\n\n<p>Armanious pointed out that these findings highlight the critical need for a better understanding of lisdexamfetamine&#8217;s effects and the importance of developing new medications with fewer side effects. The James Laboratory continues to work towards improved treatment options for BED.<\/p>\n\n\n\n<p>The study emphasizes the necessity for a more nuanced approach to treating BED, as the search for targeted and specifically developed medications continues.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers led by Rutgers Health unveiled a study that reveals mixed outcomes for patients using lisdexamfetamine, marketed as Vyvanse, a commonly prescribed stimulant for binge eating disorder (BED). &#8220;Binge eating disorder is the most common eating disorder in the United States, yet there is no drug specifically developed for the condition that affects people of [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"single-no-separators","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[13],"tags":[],"class_list":["post-16640","post","type-post","status-publish","format-standard","hentry","category-mental-health"],"acf":[],"aioseo_notices":[],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"The University Network","author_link":"https:\/\/www.tun.com\/home\/author\/funky_junkie\/"},"uagb_comment_info":0,"uagb_excerpt":"Researchers led by Rutgers Health unveiled a study that reveals mixed outcomes for patients using lisdexamfetamine, marketed as Vyvanse, a commonly prescribed stimulant for binge eating disorder (BED). &#8220;Binge eating disorder is the most common eating disorder in the United States, yet there is no drug specifically developed for the condition that affects people of&hellip;","_links":{"self":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/16640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/comments?post=16640"}],"version-history":[{"count":14,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/16640\/revisions"}],"predecessor-version":[{"id":16735,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/16640\/revisions\/16735"}],"wp:attachment":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/media?parent=16640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/categories?post=16640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/tags?post=16640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}